Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide
Authors
Keywords
-
Journal
PROSTATE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-11-01
DOI
10.1002/pros.24644
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival of patients with metastatic prostate cancer and comorbid obesity.
- (2022) Nina Cheranda et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805
- (2022) Alicia K. Morgans et al. PROSTATE
- Direct medical costs of obesity in the United States and the most populous states
- (2021) John Cawley et al. Journal of Managed Care & Specialty Pharmacy
- TAXOMET: A French prospective multicentric randomized phase II study of docetaxel plus metformin versus docetaxel plus placebo in metastatic castration-resistant prostate cancer
- (2021) PUJALTE MARTIN Marc et al. Clinical Genitourinary Cancer
- The obesity paradox in metastatic castration-resistant prostate cancer
- (2021) Alberto Martini et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system
- (2020) Paul Riviere et al. CANCER
- Obesity, race, and long‐term prostate cancer outcomes
- (2020) Adriana C. Vidal et al. CANCER
- Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
- (2019) Gerhardt Attard et al. JAMA Oncology
- Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
- (2018) Adriana C. Vidal et al. BJU INTERNATIONAL
- Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy
- (2018) Kyle A. Richards et al. JOURNAL OF UROLOGY
- Postdiagnosis Weight Change and Survival Following a Diagnosis of Early-Stage Breast Cancer
- (2016) Elizabeth M. Cespedes Feliciano et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Uncontrolled diabetes predicts poor response to novel antiandrogens
- (2016) Theodoros Karantanos et al. ENDOCRINE-RELATED CANCER
- Diabetes and Cancer: a Review of Current Knowledge
- (2016) J. Wojciechowska et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis
- (2015) A D Raval et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study
- (2014) A. C. Vidal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
- (2014) R. J. Auchus et al. ONCOLOGIST
- Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality
- (2012) Daniel E. Spratt et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer cachexia: impact, mechanisms and emerging treatments
- (2012) Vanessa C. Vaughan et al. Journal of Cachexia Sarcopenia and Muscle
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
- (2011) Rahul R. Aggarwal et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer
- (2010) J. Flanagan et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now